The US Food and Drug Administration’s head of vaccines and biologic medicines will go away the agency on the finish of April, a spokesperson confirmed to NCS on Friday.
Dr. Vinay Prasad, who joined the FDA in May, oversaw a collection of vaccine choices that attracted controversy, together with a refusal last month to assessment a brand new flu vaccine utilizing messenger RNA expertise, made by Moderna. The agency later accepted the appliance with changes.
FDA Commissioner Dr. Marty Makary has not decided on a substitute to steer the agency’s Center for Biologics Evaluation and Research, he stated in a social media post Friday.
Prasad’s departure was first reported by the Wall Street Journal.
Prasad had beforehand left the agency in July, lower than three months into the job, earlier than rejoining weeks later. That departure got here amid growing strain from White House allies together with Laura Loomer, who accused the hematologist-oncologist of being politically aligned with liberals and expressing “disdain” for President Donald Trump.
More not too long ago, CBER has been embroiled in controversy over requests for extra trial information from an organization, UniQure, creating a gene remedy for Huntington’s illness. In a uncommon transfer, officers convened a media call on Thursday to defend the FDA’s determination and assault critics.
As a professor on the University of California, San Francisco, Prasad was an early – and harsh – critic of the federal government’s Covid-19 response. He additionally criticized his predecessor within the FDA function, Dr. Peter Marks, for overseeing approvals of new medicines that Prasad argued had been supported by skinny proof.